Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475058 · ClinicalTrials.gov registry record · Phase 1
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01475058: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT01475058 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01475058, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic hematopoietic stem cell transplant for a CD19+ B cell malignancy.
Primary Outcome
Incidence of grade \>= 3 toxicity, as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 occurring from the T cell infusion through day 42 after the T cell infusion. Analysis will be performed separately in patients in complete remission (cohort A) or with detectable disease (cohort B) at day 28 post-transplant (prior to the T cell infusion). Incidence of acute GVHD occurring from the T cell infusion through day 42 after the T cell infus
Interventions
- BIOLOGICAL allogeneic cytomegalovirus-specific cytotoxic T lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT01475058 record still lists
NCT01475058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which allogeneic cytomegalovirus-specific cytotoxic T lymphocytes is the first listed.
NCT01475058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01475058 about?
NCT01475058 is a clinical study titled "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant". This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic hematopoietic stem cell transplant for a CD19+ B cell malignancy.
What is the current status of trial NCT01475058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01475058?
The interventions under investigation include: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01475058?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01475058's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia